PTPRC and oral cavity squamous cell carcinoma: We demonstrated that oral cavity squamous cell carcinomas with high levels of CD19+ tumor-infiltrating B-lymphocytes have a more favorable prognosis, irrespective of the total amount of CD45+ tumor-infiltrating lymphocytes, and that, particularly in early-stage disease, this could be used to stratify patients who do well on standard-of-care therapy and patients who might need treatment intensification such as adjuvant radiotherapy or (local) pre-operative immunotherapy regimens.